Andrea Lay-Hoon Kwa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1907581/publications.pdf

Version: 2024-02-01

62 papers 1,295 citations

393982 19 h-index 395343 33 g-index

64 all docs 64
docs citations

64 times ranked 2034 citing authors

#	Article	IF	Citations
1	Procalcitonin (PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1308-1318.	1.4	182
2	Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Review of Anti-Infective Therapy, 2007, 5, 811-821.	2.0	142
3	Prolonged infusion versus intermittent boluses of \hat{l}^2 -lactam antibiotics for treatment of acute infections: a meta-analysis. International Journal of Antimicrobial Agents, 2014, 43, 403-411.	1.1	77
4	Management of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics. Infection and Drug Resistance, 2018, Volume 11, 1959-1974.	1.1	70
5	Role of Antibiotic Prophylaxis in Necrotizing Pancreatitis: A Meta-Analysis. Journal of Gastrointestinal Surgery, 2015, 19, 480-491.	0.9	62
6	Impact of an antimicrobial stewardship programme on patient safety in Singapore General Hospital. International Journal of Antimicrobial Agents, 2012, 40, 55-60.	1.1	46
7	<i>In Vitro</i> Pharmacodynamics of Various Antibiotics in Combination against Extensively Drug-Resistant Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2015, 59, 2515-2524.	1.4	39
8	Risk Factors, Molecular Epidemiology and Outcomes of Ertapenem-Resistant, Carbapenem-Susceptible Enterobacteriaceae: A Case-Case-Control Study. PLoS ONE, 2012, 7, e34254.	1.1	38
9	Human MAIT cell cytolytic effector proteins synergize to overcome carbapenem resistance in Escherichia coli. PLoS Biology, 2020, 18, e3000644.	2.6	37
10	Molecular mechanisms of azole resistance in Candida bloodstream isolates. BMC Infectious Diseases, 2019, 19, 63.	1.3	34
11	Antimicrobial stewardship for acute-care hospitals: An Asian perspective. Infection Control and Hospital Epidemiology, 2018, 39, 1237-1245.	1.0	31
12	mcr-1in Multidrug-ResistantblaKPC-2-Producing Clinical Enterobacteriaceae Isolates in Singapore. Antimicrobial Agents and Chemotherapy, 2016, 60, 6435-6437.	1.4	29
13	Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa. MSphere, 2021, 6, .	1.3	29
14	Antimicrobial stewardship programme: a vital resource for hospitals during the global outbreak of coronavirus disease 2019 (COVID-19). International Journal of Antimicrobial Agents, 2020, 56, 106145.	1.1	28
15	Prospective audit and feedback in antimicrobial stewardship: Is there value in early reviewing within 48h of antibiotic prescription?. International Journal of Antimicrobial Agents, 2015, 45, 168-173.	1.1	27
16	Carbapenem Resistance in Gram-Negative Bacteria: The Not-So-Little Problem in the Little Red Dot. Microorganisms, 2016, 4, 13.	1.6	26
17	Emerging Role for MAIT Cells in Control of Antimicrobial Resistance. Trends in Microbiology, 2021, 29, 504-516.	3.5	25
18	Clinical Efficacy of Polymyxin Monotherapy versus Nonvalidated Polymyxin Combination Therapy versus Validated Polymyxin Combination Therapy in Extensively Drug-Resistant Gram-Negative Bacillus Infections. Antimicrobial Agents and Chemotherapy, 2016, 60, 4013-4022.	1.4	24

#	Article	IF	Citations
19	Candidemia in a major regional tertiary referral hospital $\hat{a} \in \text{``epidemiology, practice patterns and outcomes. Antimicrobial Resistance and Infection Control, 2017, 6, 27.}$	1.5	24
20	Antecedent Carbapenem Exposure as a Risk Factor for Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae and Carbapenemase-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	22
21	Procalcitonin (PCT)-guided antibiotic stewardship in Asia-Pacific countries: adaptation based on an expert consensus meeting. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1983-1991.	1.4	21
22	Impact of Antimicrobial Stewardship Program (ASP) on Outcomes in Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) in an Acute-Tertiary Care Hospital. Infectious Diseases and Therapy, 2015, 4, 15-25.	1.8	20
23	Ten-year narrative review on antimicrobial resistance in Singapore. Singapore Medical Journal, 2019, 60, 387-396.	0.3	17
24	Importance of control groups when delineating antibiotic use as a risk factor for carbapenem resistance, extreme-drug resistance, and pan-drug resistance in Acinetobacter baumannii and Pseudomonas aeruginosa: A systematic review and meta-analysis. International Journal of Infectious Diseases, 2018, 76, 48-57.	1.5	16
25	Whole genome sequencing reveals hidden transmission of carbapenemase-producing Enterobacterales. Nature Communications, 2022, 13 , .	5.8	16
26	Evaluation of Ertapenem use with Impact Assessment on Extended-Spectrum Beta-Lactamases (ESBL) Production and Gram-Negative resistance in Singapore General Hospital (SGH). BMC Infectious Diseases, 2013, 13, 523.	1.3	14
27	Incidence of a subsequent carbapenem-resistant Enterobacteriaceae infection after previous colonisation or infection: a prospective cohort study. International Journal of Antimicrobial Agents, 2021, 57, 106340.	1.1	14
28	Risk factors and outcomes associated with the isolation of polymyxin B and carbapenem-resistant Enterobacteriaceae spp.: A case–control study. International Journal of Antimicrobial Agents, 2019, 53, 657-662.	1.1	13
29	Discontinuation of antibiotic therapy within 24 hours of treatment initiation for patients with no clinical evidence of bacterial infection: a 5-year safety and outcome study from Singapore General Hospital Antimicrobial Stewardship Program. International Journal of Antimicrobial Agents, 2019, 53, 606-611.	1.1	13
30	Determining the Development of Persisters in Extensively Drug-Resistant Acinetobacter baumannii upon Exposure to Polymyxin B-Based Antibiotic Combinations Using Flow Cytometry. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	13
31	Genomic characterization of carbapenem-non-susceptible <i>Pseudomonas aeruginosa</i> in Singapore. Emerging Microbes and Infections, 2021, 10, 1706-1716.	3.0	13
32	MR1-Restricted T Cells with MAIT-like Characteristics Are Functionally Conserved in the Pteropid Bat Pteropus alecto. IScience, 2020, 23, 101876.	1.9	13
33	Risk of swallowingâ€related chest infections in patients with nasopharyngeal carcinoma treated with definitive intensityâ€modulated radiotherapy. Head and Neck, 2016, 38, E1660-5.	0.9	11
34	Using an Adenosine Triphosphate Bioluminescent Assay to Determine Effective Antibiotic Combinations against Carbapenem-Resistant Gram Negative Bacteria within 24 Hours. PLoS ONE, 2015, 10, e0140446.	1.1	10
35	Utility and Applicability of Rapid Diagnostic Testing in Antimicrobial Stewardship in the Asia-Pacific Region: A Delphi Consensus. Clinical Infectious Diseases, 2022, 74, 2067-2076.	2.9	10
36	Optimisation of Antimicrobial Dosing Based on Pharmacokinetic and Pharmacodynamic Principles. Indian Journal of Medical Microbiology, 2017, 35, 340-346.	0.3	9

#	Article	IF	Citations
37	Rapid diagnostic testing for antimicrobial stewardship: Utility in Asia Pacific. Infection Control and Hospital Epidemiology, 2021, 42, 864-868.	1.0	8
38	Antibiotic stewardship program (ASP) in palliative care: antibiotics, to give or not to give. European Journal of Clinical Microbiology and Infectious Diseases, 2021, , 1.	1.3	8
39	An Observational Study on Early Empiric versus Culture-Directed Antifungal Therapy in Critically Ill with Intra-Abdominal Sepsis. Critical Care Research and Practice, 2014, 2014, 1-8.	0.4	7
40	Candida Surveillance in Surgical Intensive Care Unit (SICU) in a Tertiary Institution. BMC Infectious Diseases, 2015, 15, 256.	1.3	7
41	Cost effectiveness of an antimicrobial stewardship programme. International Journal of Antimicrobial Agents, 2015, 46, 594-595.	1.1	7
42	In vitro Pharmacodynamics and PK/PD in Animals. Advances in Experimental Medicine and Biology, 2019, 1145, 105-116.	0.8	7
43	Integrated pharmacokinetic–pharmacodynamic modeling to evaluate empiric carbapenem therapy in bloodstream infections. Infection and Drug Resistance, 2018, Volume 11, 1591-1596.	1.1	6
44	Potent Antiviral and Antimicrobial Polymers as Safe and Effective Disinfectants for the Prevention of Infections. Advanced Healthcare Materials, 2022, 11, e2101898.	3.9	6
45	In vitro Bactericidal Activities of Combination Antibiotic Therapies Against Carbapenem-Resistant Klebsiella pneumoniae With Different Carbapenemases and Sequence Types. Frontiers in Microbiology, 2021, 12, 779988.	1.5	5
46	Hospital Pharmacists and Antimicrobial Stewardship: A Qualitative Analysis. Antibiotics, 2021, 10, 1441.	1.5	4
47	<i>In Vitro</i> Pharmacodynamics of Fosfomycin against Carbapenem-Resistant Enterobacter cloacae and Klebsiella aerogenes. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	3
48	Quantification of Human MAIT Cell-Mediated Cellular Cytotoxicity and Antimicrobial Activity. Methods in Molecular Biology, 2020, 2098, 149-165.	0.4	3
49	Will Ceftazidime-Avibactam Replace Polymyxins in Asia?. Clinical Infectious Diseases, 2021, 73, 1743-1744.	2.9	2
50	Quantification of Fosfomycin in Combination with Nine Antibiotics in Human Plasma and Cation-Adjusted Mueller-Hinton II Broth via LCMS. Antibiotics, 2022, 11, 54.	1.5	2
51	A Population Pharmacokinetic Model of Epidural Lidocaine in Geriatric Patients: Effects of Low-Dose Dopamine. Therapeutic Drug Monitoring, 2008, 30, 379-389.	1.0	1
52	Do antimicrobial stewardship programme interventions reduce the rate of and protect against Clostridium difficile infection?. Journal of Global Antimicrobial Resistance, 2019, 17, 312-315.	0.9	1
53	Discontinuation of Antibiotics in Patients with Neurological Conditions – A Study on the Impact of an Antimicrobial Stewardship Program (ASP) in a Tertiary Institution. International Journal of Antimicrobial Agents, 2020, 56, 106038.	1.1	1
54	213Impact of Antimicrobial Stewardship Strategies on Antimicrobial Use: A Systematic Review. Open Forum Infectious Diseases, 2014, 1, S94-S94.	0.4	0

#	Article	IF	CITATIONS
55	Nonattenuated Polymyxin B Used for the Treatment of Extreme-Drug ResistantAcinetobacter baumannii-Related Infections in Patients with Preexisting End Stage Renal Failure. Case Reports in Infectious Diseases, 2014, 2014, 1-3.	0.2	0
56	inPhocus: Current State and Challenges of Phage Research in Singapore. Phage, 2022, 3, 6-11.	0.8	О
57	Title is missing!. , 2020, 18, e3000644.		O
58	Title is missing!. , 2020, 18, e3000644.		0
59	Title is missing!. , 2020, 18, e3000644.		O
60	Title is missing!. , 2020, 18, e3000644.		0
61	Title is missing!. , 2020, 18, e3000644.		O
62	Title is missing!. , 2020, 18, e3000644.		0